BAX 802 in CHA With Inhibitors

Summary

The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.

Timeline

Start

2016-12-22

Primary completion

2021-01-22

Completion

2021-01-22

Outcome

Outcome not reported

Stopped: “Takeda has determined that the benefit/risk profile does not support continuation of the surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population.”

Drugs

Indications